ATG5 and prostate cancer: For example, deletion of Atg5 or Atg7 in Pten-/--driven prostate cancer, KrasG12D- or BrafV600E-driven lung cancer, or KrasG12D-driven pancreatic ductal adenocarcinoma, suppresses tumor growth.